CardiacWire

MARCH 29, 2025

IVL is a minimally invasive medical catheter-based procedure that treats calcified plaque in blood vessels. With the FDA nod, Abbott can now evaluate the IVL system in treating severe calcification in coronary arteries prior to stenting.

Plaque 59

Plaque Interventional Cardiology Stents Stent 59

DAIC

JUNE 18, 2024

The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronary artery disease. This restores the vessel viability and hemodynamic modulation by returning pulsatility, compliance, adaptive blood flow volume, and plaque stabilization and regression.

Coronary Artery Disease 105

Coronary Artery Disease Technology Stents Stent 105

DAIC

MARCH 1, 2024

Food and Drug Administration ( FDA ) approval for the AGENT Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease. ISR is the obstruction or narrowing of a stented vessel by plaque or scar tissue. vs. 28.7%; P=0.006). vs. 28.7%; P=0.006).

Stents 105

Stents Stent Coronary Artery Disease Angioplasty 105

DAIC

APRIL 12, 2024

a pioneering medical technology company specializing in cardiovascular interventional devices, today announced that its groundbreaking Acolyte Image Guided Crossing and Re-Entry Catheter System has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration ( FDA ).

Technology 111

Technology Cardiovascular Interventions Coronary Artery Disease Innovation 111

ADN Center of Excellence

SEPTEMBER 27, 2023

Why IVUS and OCT Are Vital These technologies aren't just extras; they are the ticket to enhanced diagnostic accuracy and improved patient results. IVUS reveals plaque characteristics, optimal stent usage, and vessel measurements. This powerful duo empowers cardiologists to make well-informed choices.

Education 52

Education Best Practices Stents Stent 52

Dr. Smith's ECG Blog

MARCH 28, 2017

She was treated medically for NonSTEMI, pending next day cath, which showed ulcerated plaque and a 60% thrombotic stenosis in the LAD distal to the first diagonal. It was stented. Wall motion abnormalities are very hard to see, even with advanced Speckle Tracking technology. Learning Points : 1. Use the 4-variable formula!!

STEMI 40

STEMI Risk Factors Bicuspid/Mitral Ultrasound 40

Dr. Smith's ECG Blog

OCTOBER 23, 2022

She was treated medically for NonSTEMI, pending next day cath, which showed ulcerated plaque and a 60% thrombotic stenosis in the LAD distal to the first diagonal. It was stented. Wall motion abnormalities are very hard to see, even with advanced Speckle Tracking technology. Learning Points : 1. Use the 4-variable formula!!

STEMI 40

STEMI Chest Pain Hospital Risk Factors 40